Beretta Proposes $44.80 Partial Tender Offer for Sturm Ruger (RGR)

Why This Deal Is Unusual

This is not a standard tender offer. Sturm, Ruger & Company (NYSE: RGR), one of the largest firearms manufacturers in the United States, is the target of an aggressive campaign by Beretta Holding S.A. — the Luxembourg-based parent of Fabbrica d'Armi Pietro Beretta, the Italian gunmaker whose history stretches back nearly 500 years. Beretta is already Ruger's largest shareholder at 9.95%, and this proposed tender offer is one piece of a multi-pronged strategy that also includes a proxy fight for board seats.

Partial tender offers by strategic competitors are rare. Most tender offers seek 100% of shares. Here, Beretta is explicitly seeking only 20.05% of shares it doesn't already own, which would bring its total stake to roughly 30%. Beretta says it does not intend to take control of Ruger, instead framing the move as a path toward a "strategic partnership." Ruger's board sees it differently, calling the campaign a "creeping takeover."

For investors holding RGR, the key question is whether this tender offer will ever actually launch — and if it does, whether you'll be able to sell all your shares at the premium price, or only a fraction of them.

The Offer (As Proposed)

Beretta Holding filed a preliminary SC TO-C with the SEC on March 25, 2026, signaling its intention to launch a tender offer for up to 20.05% of Ruger's outstanding common shares at $44.80 per share in cash. Based on approximately 15.94 million shares outstanding and Beretta's existing 1.587 million share position, the offer would target roughly 3.2 million shares for a total cost of approximately $143 million.

The proposed price represents:

• A ~9.1% premium to the current market price of $41.07
• A ~20% premium to the 60-day volume-weighted average price
• A price comfortably within the 52-week range of $28.81 – $47.13

This is a partial offer, so even if it launches and you tender, proration is virtually certain. If more than 20.05% of non-Beretta shares are tendered, Beretta would buy a proportional amount from each tendering shareholder and return the rest. With Beretta seeking only ~22% of the shares it doesn't already own, the math means most shareholders would get only a fraction of their shares purchased at the premium price.

The Poison Pill Problem

The single biggest obstacle to this tender offer launching is Ruger's shareholder rights plan, adopted on October 14, 2025. The plan sets a 10% ownership threshold — if any person or group crosses it without board approval, other shareholders can purchase additional shares at a steep discount, massively diluting the acquirer's position.

Beretta currently sits at 9.95% — just below the trigger. It cannot buy a single additional share without tripping the poison pill unless the board grants an exemption. The entire tender offer is conditioned on receiving that exemption, which makes this more of a negotiating tactic and public pressure campaign than a firm offer shareholders can act on today.

The Ruger board has not granted the exemption. In its public response, the board confirmed receipt of Beretta's letter and said it would "assess Beretta's letter and respond in due course" in consultation with its financial and legal advisors. The tone has been adversarial: Ruger has accused Beretta of a "creeping takeover" and launched a dedicated website to make its case to shareholders ahead of the annual meeting.

The Proxy Fight

The tender offer proposal arrived in the middle of an already-heated proxy contest. Here is how the situation escalated:

The proxy fight and the tender offer are strategically linked. If Beretta wins four of nine board seats at the annual meeting, a reconstituted board could vote to waive the poison pill, clearing the path for the tender offer to launch. This is the playbook: the tender offer applies public pressure on shareholders to support Beretta's board nominees, and the board nominees — if elected — unlock the tender offer.

What Beretta Wants

Beretta says it wants a "strategic partnership" with Ruger — not control. At 30% ownership, Beretta would remain a minority shareholder. But a 30% stake combined with four board seats out of nine would give Beretta enormous influence over Ruger's direction.

The strategic logic is straightforward. Beretta is one of the world's oldest and largest firearms manufacturers, dominant in European and military markets. Ruger is the largest publicly traded U.S. firearms company, with deep penetration in the American civilian and sporting market. A closer relationship could mean shared manufacturing capabilities, distribution partnerships, or joint product development — the kind of synergies that a competitor-turned-partner arrangement can unlock.

Beretta has also criticized Ruger's financial performance, noting that net income has declined more than 90% from its peak and is at its lowest level in a decade. This is a common activist playbook: build a stake, argue management is destroying value, propose changes, and use the threat of further action to force concessions.

What This Means for Shareholders

If you own RGR shares today, here is the practical situation:

You cannot tender yet. The offer has not commenced. This is a preliminary communication only. Until the board waives the poison pill (or Beretta launches regardless and litigates), there is no formal tender offer to respond to.

The spread is real but conditional. At $41.07, shares trade roughly 9.1% below the proposed $44.80 offer price. That spread reflects the market's judgment on the probability that this offer actually launches and closes, adjusted for the proration risk inherent in a partial tender.

Proration would limit your upside. Even if the offer launches and you tender all your shares, Beretta is only buying 20.05% of outstanding shares (excluding its existing stake). If every non-Beretta shareholder tenders, you would sell only about 22% of your shares at $44.80 and keep the rest. Your blended return would be far less than 9.1%.

The proxy fight matters more in the near term. The May 29 annual meeting is the next inflection point. If Beretta wins enough board seats, the dynamics shift significantly — toward a poison pill waiver, a negotiated deal, or potentially a full acquisition down the road.

Risks

• The poison pill may never be waived. If Ruger's board refuses to grant an exemption and Beretta loses the proxy fight, the tender offer cannot launch as proposed. Beretta would need to find another path — litigation, a revised proposal, or simply waiting out the poison pill's October 2026 expiration.
• This could be a negotiating tactic that never becomes a real offer. The SC TO-C filing gives Beretta maximum flexibility. It is under no obligation to actually commence the tender offer, even if the poison pill is waived.
• Proration risk is substantial. In a partial tender offer, oversubscription is common. The effective premium per share could be significantly diluted once proration is applied.
• Regulatory and political risk. A European firearms company acquiring a significant stake in a major American gunmaker could attract scrutiny from regulators or politicians, particularly given the sensitivity of the firearms industry in U.S. politics. No specific regulatory filing requirements have been disclosed yet.
• RGR could trade down if the campaign fails. The stock has appreciated in part because of takeover speculation. If Beretta loses the proxy fight and walks away, shares could revert toward the lower end of the 52-week range.
• Beretta says it doesn't want control — but 30% plus board seats is a lot of influence. Ruger's framing of this as a "creeping takeover" resonates because a 30% stake is often a precursor to a full acquisition. Shareholders should consider whether they are comfortable with Beretta as a dominant minority shareholder.

Key Terms

• Proposed offer price: $44.80 per share, all cash
• Shares sought: Up to 20.05% of outstanding shares (~3.2 million shares)
• Total deal value: ~$143 million
• Acquirer: Beretta Holding S.A. (Luxembourg), parent of Fabbrica d'Armi Pietro Beretta
• Beretta's current stake: 9.95% (approximately 1.587 million shares)
• Post-tender ownership target: ~30%
• Condition: Waiver of Ruger's shareholder rights plan (poison pill)
• Offer status: Not yet commenced — SC TO-C preliminary communication only
• Annual meeting: Expected May 29, 2026 (proxy contest for four board seats)
• Legal advisors: Olshan Frome Wolosky LLP (for Beretta); Reed Smith LLP (for Beretta)
• Poison pill expiration: October 13, 2026

This analysis is for informational purposes only and does not constitute investment advice. The proposed tender offer has not commenced. Read the complete SC TO-C filing and consult your own advisors before making any decisions.